Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Adalimumab/ustekinumab

Lack of efficacy, neurologic symptoms and hypesthesia

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ottevanger R, et al. Addendum to "Remittance of primary cutaneous CD30+ lymphoproliferative disorder in a patient on adalimumab". JAAD Case Reports 45: 34, Mar 2024. Available from: URL: https://dx.doi.org/10.1016/j.jdcr.2023.12.018 Ottevanger R, et al. Addendum to "Remittance of primary cutaneous CD30+ lymphoproliferative disorder in a patient on adalimumab". JAAD Case Reports 45: 34, Mar 2024. Available from: URL: https://dx.doi.org/10.1016/j.jdcr.2023.12.018
Metadaten
Titel
Adalimumab/ustekinumab
Lack of efficacy, neurologic symptoms and hypesthesia
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55401-3

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Tozinameran

Case report

Adalimumab

Case report

Blinatumomab